Why is Transgene Biotek falling/rising?

As of 28-Jul, Transgene Biotek Ltd's stock price is currently at 4.75, reflecting a decrease of 0.08 or 1.66%. The stock has shown mixed performance in recent periods, with a 1-week return of +1.06% and a 1-month return of +7.47%, indicating some short-term recovery. However, it has significantly underperformed in the year-to-date period with a decline of 30.45%. Today's price summary indicates that the stock has underperformed its sector by 0.71%, and there has been a notable drop in investor participation, with delivery volume falling by 43.73% compared to the 5-day average. Additionally, while the stock is trading higher than its 50-day and 100-day moving averages, it is lower than the 5-day, 20-day, and 200-day moving averages, suggesting a lack of momentum. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement.
Broader market context shows that while Transgene Biotek has had a positive return over the past week and month, it has still lagged behind the benchmark Sensex, which has declined by 1.59% over the same week and 3.77% over the month. Year-to-date, the stock's performance is starkly contrasted by the Sensex's gain of 3.52%, highlighting a significant underperformance in the broader market context. Over the past year, Transgene Biotek has seen a drastic decline of 51.63%, while the Sensex has only slightly decreased by 0.54%. This disparity indicates that the stock is facing challenges that are not present in the broader market, contributing to its recent price decline.